Work

21P Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer

Year: 2024

Type: article

Abstract: Background: Ovarian cancer is the most lethal gynecological malignancy worldwide and is known to have a poor prognosis among gynecological cancers.Recently, PD-1/ PD-L1 inhibitors have demonstrated promising clinical outcomes in the treatment of OC.However, only about 20% of patients respond to these therapies, highlighting the need for improved patient selection.LncRNAs are significantly involved in tumor proliferation, apoptosis, migration, and metastasis and have significant associations with immune cell infiltration and the cancer cell response to anti-PD-1 immunotherapy in various tumors.Based on reports that immune-related lncRNAs play a role in regulating the PD-1/PD-L1 mechanism, this study aims to identify predictive biomarkers for ovarian cancer.Methods: We analyzed the mRNA and protein levels of PD-L1 in OC patient tissues and classified them into high and low PD-L1 expression groups.We performed lncRNA microarray analysis on the classified groups.As a result, we identified MIR4435-2HG as lncRNA associated with PD-L1 overexpression.Furthermore, MIR4435-2HG knockdown were conducted.Other features, including cell growth, apoptosis, migration and invasion were also analyzed.Results: A positive correlation between PD-L1 and MIR4435-2HG was observed in both OC tissues and cell lines.Knockdown of MIR4435-2HG in OC cell lines resulted in decreased PD-L1 expression and induce cellular apoptosis and inhibit cell migration and invasion.Moreover, GO analysis revealed that MIR4435-2HG is associated to immune-related genes.Conclusions: Therefore, this study suggests that the lncRNA MIR4435-2HG associated with PD-L1 may be used as a predictive biomarker and therapeutic target in ovarian cancer.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100903

Authors: L. Wu, X. Hao, P. Xing, J. Li

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170